Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)

NCT04196491 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04196491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04196491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
May 27, 2020
Completion date
June 7, 2023
Enrollment
13 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma